Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- Check6 days agoChange DetectedAdded recruitment-status notice 'No longer looking for participants' and new guidance sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study'). Updated the 'Intervention / Treatment' heading to 'Intervention/Treatment' and bumped the revision tag to v3.6.0 (removing v3.5.5).SummaryDifference0.5%

- Check13 days agoChange DetectedThe bottom revision label was updated from v3.5.4 to v3.5.5, reflecting a minor template/version update to the page. This update does not modify any study data or content on the ClinicalTrials.gov record.SummaryDifference0.1%

- Check20 days agoChange DetectedFooter attributions for the sponsor and related links have been removed. This changes the page's display of institutional context and credits associated with the study record.SummaryDifference0.2%

- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedA new revision tag v3.5.4 was added to the page’s revision history, replacing v3.5.3. This reflects an update to the document’s versioning without altering its substantive content.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page’s footer shows an updated site/application revision from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check64 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.